Cidara Therapeutics, Inc.
CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$221.42
52W Low$15.22
Cidara Therapeutics, Inc. (CDTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CDTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.27M | $23.28M | $64.45M | $49.57M | $12.07M |
| Cost of Revenue | $0.00M | $36.76M | $0.00M | $73.09M | $0.00M |
| Gross Profit | $1.27M | ($13.48M) | $64.45M | ($23.52M) | $12.07M |
| Gross Margin %(computed) | 100.00% | -57.90% | 100.00% | -47.44% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $156.76M | $36.76M | $77.41M | $73.09M | $68.02M |
| G&A Expenses | $20.61M | $13.58M | $20.55M | $18.74M | $15.90M |
| Total Operating Expenses | $177.38M | $13.58M | $97.95M | $18.74M | $83.92M |
| Operating Income | ($176.10M) | ($27.06M) | ($33.50M) | ($42.26M) | ($71.85M) |
| Operating Margin %(computed) | — | -116.22% | -51.98% | -85.24% | -595.42% |
| Interest Income | $5.81M | $2.00M | $0.19M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.26M |
| Income Before Tax | ($170.29M) | ($25.07M) | ($33.31M) | ($42.47M) | ($72.11M) |
| Income Tax Expense | $0.00M | $0.01M | $0.27M | $0.00M | $0.00M |
| Net Income | ($169.83M) | ($22.93M) | ($33.58M) | ($42.47M) | ($72.11M) |
| Net Margin %(computed) | — | -98.49% | -52.11% | -85.67% | -597.59% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-26.75 | $-5.25 | $-9.61 | $-16.20 | $-36.03 |
| Wtd Avg Shares | 6.35M | 4.37M | 3.49M | 2.62M | 2.08M |
| EBITDA | ($175.87M) | ($26.95M) | ($33.36M) | ($42.07M) | ($70.80M) |
| EBITDA Margin %(computed) | — | -115.74% | -51.76% | -84.86% | -586.72% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Cidara Therapeutics, Inc. data
About Cidara Therapeutics, Inc. (CDTX) Income Statement
Cidara Therapeutics, Inc. (CDTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CDTX reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.17B) — a net profit margin of -13319.76%.
Frequently asked questions
CDTX · 4 questionsCidara Therapeutics, Inc. (CDTX) reported revenue of $0.00B for 2024, down 94.5% year-over-year.
CDTX revenueCDTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08